Meta-Analysis A Systematic Review and Meta-Analysis of the Sex Ratio for Barrett’s Esophagus, Erosive Reflux Disease, and Nonerosive Reflux Disease
暂无分享,去创建一个
[1] P. Vestergaard,et al. Oesophageal disease revealed by endoscopy in 1,000 patients referred primarily for gastroscopy. , 2009, Acta medica Scandinavica.
[2] D. Forman,et al. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. , 2005, American journal of epidemiology.
[3] E. Quigley. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? , 2004, Best practice & research. Clinical gastroenterology.
[4] M. Solaymani-Dodaran,et al. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux , 2004, Gut.
[5] P. Malfertheiner,et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. , 2004, Journal of clinical epidemiology.
[6] F. Pace,et al. Gastroesophageal Reflux Disease: A Typical Spectrum Disease (A New Conceptual Framework is Not Needed) , 2004, American Journal of Gastroenterology.
[7] R. Sampliner,et al. Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] R. Loffeld,et al. Rising Incidence of Reflux Oesophagitis in Patients Undergoing Upper Gastrointestinal Endoscopy , 2004, Digestion.
[9] V. Savarino,et al. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non‐erosive reflux disease , 2003, Alimentary pharmacology & therapeutics.
[10] P. I. Reed,et al. Characteristics and regional variations of patients with Barrett's oesophagus in the UK , 2003, European journal of gastroenterology & hepatology.
[11] P. Malfertheiner,et al. Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease — an analysis based on the ProGERD initiative , 2003, Alimentary pharmacology & therapeutics.
[12] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[13] Christopher P. Wild,et al. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions , 2003, Nature Reviews Cancer.
[14] R. Cestari,et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.
[15] W. Wong,et al. Prevalence, clinical spectrum and health care utilization of gastro‐oesophageal reflux disease in a Chinese population: a population‐based study , 2003, Alimentary pharmacology & therapeutics.
[16] A. Gavin,et al. Mortality in Barrett’s oesophagus: results from a population based study , 2003, Gut.
[17] P. Malfertheiner,et al. Prevalence of extra‐oesophageal manifestations in gastro‐oesophageal reflux disease: an analysis based on the ProGERD Study , 2003, Alimentary pharmacology & therapeutics.
[18] A. Barkun,et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study , 2003, Alimentary pharmacology & therapeutics.
[19] A. Clarke,et al. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma , 2003, Journal of gastroenterology and hepatology.
[20] A. Damiano,et al. Reductions in Symptom Distress Reported by Patients with Moderately Severe, Nonerosive Gastroesophageal Reflux Disease Treated with Rabeprazole , 2003, Digestive Diseases and Sciences.
[21] D. Schilling,et al. Natural course of erosive reflux disease: Results of a prospective study with a mean follow up of 6 years , 2003 .
[22] J. Soares,et al. Risk of neoplastic progression in Barrett's esophagus: Data from a prospective surveillance program in Portugal , 2003 .
[23] J. Dillon,et al. Gender differences in the epidemiology of GORD , 2003 .
[24] A. Ootani,et al. Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women. , 2003, Journal of gastroenterology.
[25] P. Parrilla,et al. Long-Term Results of a Randomized Prospective Study Comparing Medical and Surgical Treatment of Barrett’s Esophagus , 2003, Annals of surgery.
[26] D. Corley,et al. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States , 2002, Cancer.
[27] I. Kunnamo,et al. The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants , 2002, American Journal of Gastroenterology.
[28] G. Triadafilopoulos,et al. Prevalence of Barrett's esophagus in asymptomatic individuals. , 2002, Gastroenterology.
[29] R. Fass,et al. Gastroesophageal reflux disease—should we adopt a new conceptual framework? , 2002, American Journal of Gastroenterology.
[30] V. Moreno,et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995 , 2002, International journal of cancer.
[31] W. Orr,et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial , 2002, American Journal of Gastroenterology.
[32] S. Spechler,et al. Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.
[33] R. Hegedus,et al. Onset of symptom relief with rabeprazole: a community‐based, open‐label assessment of patients with erosive oesophagitis , 2002, Alimentary pharmacology & therapeutics.
[34] J. Devière,et al. Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources , 2002, European journal of gastroenterology & hepatology.
[35] G. Lapertosa,et al. Risk factors for Barrett's esophagus: A case‐control study , 2002, International journal of cancer.
[36] H. El‐Serag,et al. Risk Factors for the Severity of Erosive Esophagitis in Helicobacter pylori -Negative Patients with Gastroesophageal Reflux Disease , 2002, Scandinavian journal of gastroenterology.
[37] J. Lagergren,et al. Body Mass and Reflux Oesophagitis: an Oestrogen-dependent Association? , 2002, Scandinavian journal of gastroenterology.
[38] J. Peters,et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. , 2001, Archives of surgery.
[39] R. Mittal,et al. Sustained esophageal contraction: a motor correlate of heartburn symptom. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[40] C. Gutschow,et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males , 2001, Cancer.
[41] V. Eckardt,et al. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. , 2001, The American journal of medicine.
[42] Y. Jeen,et al. Prevalence of endoscopic reflux esophagitis among Koreans , 2001, Journal of gastroenterology and hepatology.
[43] L. Melton,et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota , 2001, Gut.
[44] R. Fass,et al. Nonerosive Reflux Disease— Current Concepts And Dilemmas , 2001, American Journal of Gastroenterology.
[45] T. Kennedy,et al. The prevalence of gastro‐oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms , 2000, Alimentary pharmacology & therapeutics.
[46] R. Playford,et al. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study , 2000, BMJ : British Medical Journal.
[47] D. Forman,et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.
[48] R. Sandler,et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.
[49] J. Richter,et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. , 2000, Archives of internal medicine.
[50] P. Kahrilas,et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. , 2000, Archives of internal medicine.
[51] B. Reid,et al. Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus , 2000, Annals of Internal Medicine.
[52] A. Csendes,et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[53] J. Mecklin,et al. Gastroesophageal Reflux Disease: Prevalence, Clinical, Endoscopic and Histopathological Findings in 1,128 Consecutive Patients Referred for Endoscopy due to Dyspeptic and Reflux Symptoms , 2000, Digestion.
[54] R. Stanton,et al. Heartburn: Community perceptions , 2000, Journal of gastroenterology and hepatology.
[55] T. Shimosegawa,et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis , 1999, American Journal of Gastroenterology.
[56] J. Hyams. Functional gastrointestinal disorders. , 1999, Current opinion in pediatrics.
[57] J. Wilson,et al. Functional esophageal disorders , 1999, Gut.
[58] G. Falk,et al. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999, American Journal of Gastroenterology.
[59] P. Malfertheiner,et al. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. , 1999, Gastroenterology.
[60] S. I. Lee,et al. Reflux esophagitis and its relationship to hiatal hernia. , 1999, Journal of Korean medical science.
[61] A. Lindgren,et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.
[62] B. Naliboff,et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. , 1998, Gastroenterology.
[63] P. Malfertheiner,et al. The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case‐control study , 1998, European journal of gastroenterology & hepatology.
[64] L. Lundell,et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. , 1997, Scandinavian journal of gastroenterology.
[65] M. Helfand,et al. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. , 1997, The American journal of gastroenterology.
[66] R. Sampliner,et al. Erosive Esophagitis and Barrett's Esophagus in Taiwan (A Higher Frequency than Expected) , 1997, Digestive Diseases and Sciences.
[67] H. Smart,et al. Cost effectiveness of detecting Barrett's cancer. , 1996, Gut.
[68] A. Axon,et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis , 1996, Alimentary pharmacology & therapeutics.
[69] R. Goyal,et al. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. , 1996, Gastroenterology.
[70] J. Galmiche,et al. Oesophageal sensitivity to acid in patients with non-cardiac chest pain: is the oesophagus hypersensitive? , 1995, European journal of gastroenterology & hepatology.
[71] W. Hop,et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.
[72] P Laippala,et al. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. , 1995, Annals of medicine.
[73] O. Nyrén,et al. The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. , 1994, Scandinavian journal of gastroenterology.
[74] Nicholas J. Talley,et al. U. S. Householder survey of functional gastrointestinal disorders , 1993, Digestive Diseases and Sciences.
[75] L. Lööf,et al. The incidence of reflux oesophagitis. A study of endoscopy reports from a defined catchment area in Sweden. , 1993, Scandinavian journal of gastroenterology.
[76] A. Csendes,et al. Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis. , 1993, Gut.
[77] N. Walker,et al. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.
[78] F. Ellis,et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. , 1991, Archives of internal medicine.
[79] J. Fraumeni,et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.
[80] D J Ballard,et al. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. , 1990, Gastroenterology.
[81] J. G. van den Tweel,et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.
[82] B. Cooper,et al. Barrett's oesophagus: a clinical study of 52 patients. , 1987, The Quarterly journal of medicine.
[83] A. Blum,et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. , 1986, Gastroenterology.
[84] W. C. Watson,et al. Management of adenocarcinoma in a columnar-lined esophagus. , 1985, The Annals of thoracic surgery.
[85] D. Castell,et al. Symptomatic gastroesophageal reflux: Incidence and precipitating factors , 1976, The American Journal of Digestive Diseases.
[86] A. Csendes,et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. , 2003, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[87] A. Garrido Serrano,et al. Clinical features and endoscopic progression of gastroesophageal reflux disease. , 2003, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[88] P. Dítě,et al. [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.
[89] R. Willén,et al. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. , 2000, Scandinavian journal of gastroenterology.
[90] P. Kahrilas,et al. Esophageal sensitivity and symptom perception in gastroesophageal reflux disease , 1999, Current gastroenterology reports.
[91] M. Vieth,et al. Short Barrett: prevalence and risk factors. , 1999, Scandinavian journal of gastroenterology.
[92] R. Mcfarland,et al. Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. , 1998, Scandinavian journal of gastroenterology.
[93] Stephen J. Sharp,et al. Meta-analysis regression , 1998 .
[94] R. Sandler,et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. , 1997, The American journal of gastroenterology.
[95] A. Csendes,et al. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. , 1997, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[96] T. Venables,et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. , 1997, Scandinavian journal of gastroenterology.
[97] J. Y. Kang,et al. Low frequency of endoscopic esophagitis in Asian patients. , 1993, Journal of clinical gastroenterology.